Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of D3S-002 Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

NCT05886920 is registered in ClinicalTrials.gov with D3 Bio (Wuxi) Co., Ltd as lead sponsor.

NCT NCT05886920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05886920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of D3S-002 Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
Lead sponsor
D3 Bio (Wuxi) Co., Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 10, 2023
Completion date
August 31, 2028
Enrollment
67 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors with mapk pathway mutations